Stockscreener 앱 받기
1.08
1.82%
-0.02
전일 마감가:
$1.10
열려 있는:
$1.09
하루 거래량:
535.65K
Relative Volume:
0.40
시가총액:
$273.14M
수익:
$14.78M
순이익/손실:
$-64.01M
주가수익비율:
-3.7591
EPS:
-0.2873
순현금흐름:
$-22.59M
1주 성능:
-2.70%
1개월 성능:
-3.57%
6개월 성능:
-44.62%
1년 성능:
-10.00%
1일 변동 폭
$1.08
$1.105
1주일 범위
$1.08
$1.135
52주 변동 폭
$1.00
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
명칭
Lineage Cell Therapeutics Inc
전화
510-871-4188
주소
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.08 | 273.14M | 14.78M | -64.01M | -22.59M | -0.2873 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 개시 | Craig Hallum | Buy |
| 2022-11-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-14 | 개시 | B. Riley Securities | Buy |
| 2021-08-19 | 개시 | Noble Capital Markets | Outperform |
| 2021-03-31 | 개시 | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
LCTX Q2 2026 Earnings: Wider-Than-Expected Loss Keeps Focus on Cell Therapy PipelineEPS Growth Rate - Vinanet
LCTX Q2 2026 Earnings: Slight EPS Miss Overshadowed as Shares Rise $0.94Revenue Surprise History - Vinanet
LCTX Q2 2026 Earnings: Modest EPS Miss Overshadowed by Clinical-Stage FocusOne-Time Loss Impact - Vinanet
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript - AOL.ca
Lineage Cell Therapeutics (LCTX) Falls 3.6% to $1.06 as Biotech Sentiment WeighsDealer Gamma - Vinanet
Lineage Cell Therapeutics Q3 EPS Reduced by HC Wainwright - MarketBeat
Lineage Cell Therapeutics (LCTX) Climbs 3.18% to $1.14 as Buyers Defend Key SupportRisk Reward Setups - Vinanet
Lineage Cell Therapeutics Q2 Earnings Call Highlights - MarketBeat
CCORF Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Lineage Cell Therapeutics, Inc. (LCTX) stock price, news, quote and history - Yahoo Finance Australia
Lineage Cell Therapeutics Balances Progress and Risk - TipRanks
Lineage Cell Therapeutics (LCTX) Stock Faces Cash Burn Despite Paper Profit - Sahm
Lineage Cell Therapeutics Inc (LCTX) Stock News Today - TradingKey
Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - biospace.com
Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Hig - GuruFocus
LCTX Looks 13.7% Undervalued on GF Value™ - GuruFocus
Transcript : Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Earnings call transcript: Lineage Cell Therapeutics posts Q2 2026 profit, extends runway - Investing.com
Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Lineage Cell: Q2 Earnings Snapshot - marketscreener.com
[10-Q] Lineage Cell Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Lineage Cell Therapeutics (LCTX) Holds Above $1.07 Support as Biotech ConsolidatesPCR Divergence - Vinanet
3 Penny Stocks With Market Caps Larger Than $40M To Watch - webull.com
Lineage Cell Therapeutics (LCTX) Nudges Higher, Consolidating Between $1.06 Support and $1.18 ResistanceOBV Breakout - vinanet.vn
Lineage Cell Therapeutics (LCTX) to Post Earnings on Thursday - MarketBeat
Lineage Cell Therapeutics, Inc. Revenue Breakdown – AMEX:LCTX - TradingView
Earnings Preview: LCTX to Report Financial Results Post-market on August 06 - Moomoo
Lineage Cell Therapeutics to announce Q2 2026 results on August 6 with business update call - Traders Union
Lineage Cell Therapeutics (LCTX) Holds Above $1.04 Support After 0.90% PullbackBPI Bull Confirmed - Vinanet
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 - Yahoo Finance
BlackRock, Inc. (LCTX) discloses 5.3% beneficial ownership in Lineage Cell - Stock Titan
Lineage Cell Therapeutics Inc (LCTX) Income Statement - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Cash Flow - TradingKey
Lineage Cell Therapeutics Inc - TradingKey
LCTX|Lineage Cell Therapeutics Inc|Price:1.035|Chg%:+0.005 - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Balance Sheet - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lineage Cell Therapeutics (LCTX) Slips 3.74% as Stock Tests Key Support LevelsFear Greed Extreme - vinanet.vn
Lineage Cell Therapeutics, Inc. Revenue Breakdown – SWB:BT3 - TradingView
Lineage Cell Therapeutics, Inc. Revenue Breakdown – LS:A2PP89 - TradingView
LCTX|Lineage Cell Therapeutics Inc|Price:1.030|Chg%:-0.035 - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OpRegen regenerative medicine program showcased at major vision event by Lineage Cell Therapeutics - Traders Union
LCTX Q1 2026 Earnings: Wider Loss as Pre-Revenue Biotech Navigates Clinical MilestonesEPS Surprise History - vinanet.vn
Lineage Cell Therapeutics (LCTX) Edges Lower as Stock Hovers Near Key SupportSupply Zone - dars.gov.et
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating - Moomoo
Lineage Cell Therapeutics Inc (LCTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):